Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. My name is Bella and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2024 Series Therapeutics Earnings Conference Call. All lines have been placed to mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star 1 again. Thank you. I would now like to turn the call over to Dr. Carlo Tanzi, Investor Relations. Please go ahead. Thank you and good morning. Our press release with the company's third quarter 2024 financial results and business updates became available at 7 a.m. Eastern time this morning and can be found on the investors and news section of the company's website. The company has also posted an updated corporate presentation to the website. I'd like to remind you that we'll be making forward-looking statements, including statements about the financial terms and future payments related to the VOW sale, the timing and results of our clinical studies and data readouts, future product candidates, development plans, and commercial opportunities, interactions with regulatory agencies, operating plans and our cash runway, our ability to generate additional capital, our planned strategic focus, and anticipated timing of any of the foregoing and other statements which are not historical facts. Actual results may differ materially. On today's call, with prepared remarks, I'm joined by Eric Schaaf, Series President and CEO, Marilla Thorell, CFO, Dr. Lisa Von Mulkey, Chief Medical Officer, and Dr. Terry Young, Chief Commercial and Strategy Officer. Additional members ...